Xinfeng Cai

ORCID: 0000-0003-0809-7102
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Antibiotics Pharmacokinetics and Efficacy
  • Antibiotic Resistance in Bacteria
  • Hemoglobinopathies and Related Disorders
  • Pharmacological Effects and Toxicity Studies
  • Neutropenia and Cancer Infections
  • Epilepsy research and treatment
  • Neonatal Health and Biochemistry
  • Histone Deacetylase Inhibitors Research
  • Antibiotic Use and Resistance
  • Pneumocystis jirovecii pneumonia detection and treatment
  • Signaling Pathways in Disease

Shanxi Medical University
2022-2025

High-dose (HD) tigecycline is often required for severe multidrug-resistant gram-negative infections in liver failure patients, despite package recommendations to halve the dose those with impairment. This study evaluated efficacy and safety of different doses this population. A retrospective cohort 192 patients Child-Pugh grade C was divided into label-dose (LD), standard-dose (SD), HD groups. Primary secondary outcomes included microbial eradication, mortality, adverse effects. The SD...

10.1080/14787210.2025.2472346 article EN Expert Review of Anti-infective Therapy 2025-02-24

Platelet decline is a frequent side effect of valproic acid, medication commonly prescribed to prevent seizures in neurosurgical patients. However, the risk factors for acid-associated platelet remain poorly understood, and it remains unknown whether linezolid or levetiracetam combination with acid associated thrombocytopenia, as both drugs could lead decrease count. This three center, retrospective nested case–control study aimed develop predictive model prediction acid-induced cohort 356...

10.1038/s41598-025-94754-z article EN cc-by-nc-nd Scientific Reports 2025-03-22

Background: Tigecycline and cefoperazone/sulbactam can cause coagulation disorders; tigecycline may also lead to hypofibrinogenemia, raising safety concerns. This study aimed investigate whether plus increases the risk of bleeding compared with other tigecycline-based combination therapies identify factors for tigecycline-associated hypofibrinogenemia. Methods: In this multi-method, multicenter, retrospective study, baseline variables were using a cohort hypofibrinogenemia case-control...

10.3389/fphar.2023.1182644 article EN cc-by Frontiers in Pharmacology 2023-06-07

Tigecycline has been widely used for multi-drug resistant bacterial infections in China. Although many studies have reported the risk factors tigecycline-induced hypofibrinogenemia, it remains unknown whether valproic acid or voriconazole combination with tigecycline is related to fibrinogen decline, as both drugs could lead coagulation disorders. The aim of study was develop a nomogram prediction hypofibrinogenemia. This multi-center retrospective case-control study. primary outcomes...

10.1016/j.ijantimicag.2023.107062 article EN cc-by-nc-nd International Journal of Antimicrobial Agents 2023-12-16

Abstract Backgrounds Tigecycline has a broad spectrum of antimicrobial activity and been approved for the treatment complicated intra-abdominal infections. However, it is debatable whether tigecycline should be used alone or in combination. This study aimed to investigate plus β-lactam antibiotics (combination therapy [CT] group) are superior (monotherapy [MT] non-critically ill infection patients after tumor surgery. Methods was multicenter, retrospective cohort study. The primary outcome...

10.1186/s12885-023-11169-7 article EN cc-by BMC Cancer 2023-07-20

This study aimed to investigate the relationship between gene polymorphisms and clinical factors with concentrations of valproic acid (VPA) in adult patients who underwent neurosurgery China.A total 531 serum concentration samples at steady state were collected from 313 develop a population pharmacokinetic (PPK) model. Data analysis was performed using nonlinear mixed effects modeling. Covariates included demographic parameters, biological characteristics, genetic polymorphism. Bootstrap...

10.1007/s40120-022-00419-8 article EN cc-by-nc Neurology and Therapy 2022-11-18
Coming Soon ...